Circulating Noncoding RNAs Have a Promising Future Acting as Novel Biomarkers for Colorectal Cancer

Table 2

Panels of circulating miRNAs as diagnostic and early screening biomarkers for CRC.

Panel of ncRNA	Body fluid	Number of ncRNAs	Numbers of patients	Numbers of controls	AUC	Sensitivity	Specificity	Reference
miR-21↑, let-7g↑, miR-31↓, miR-92a↓, miR-181b↓, miR-203↓	Serum	6	113	89	0.923	—	—	[81]
miR-19a↑, miR-19b↑, miR-15b↑	Plasma	3	63	73	0.84	78.57%	79.25%	[78]
miR-409-3p↑, miR-7↓, miR-93↓	Plasma	3	124	117	0.897	82%	89%	[32]
miR-29c↓, miR-122↑, miR-192↓, miR-374a↓	Plasma	4	55	55	0.98 (discriminate CRC from CAA)	—	—	[79]
lnc-CCAT1↑, lnc-HOTAIR↑	Plasma	2	32	32	0.954	—	—	[82]
lnc-LOC285194↑, lnc-RP11-462C24.1↑, lnc-Nbla12061↑	Serum	3	71	70	0.793	68.33%	86.89%	[37]
lnc-BANCR↑, lnc-NR-026817↓, lnc-NR-029373↓, lnc-NR-034119↓	Serum	4	240	240	0.881	89.17%	75.83%	[35]

Note: ↑, upregulated; ↓, downregulated; —, not mentioned. CAA, colorectal advanced adenoma; CCAT1, colon cancer-associated transcript 1; HOTAIR, HOX transcript antisense intergenic RNA; BANCR, BRAF-activated noncoding RNA.